FDA Approves Label Update to Include Additional Data for Otezla ® (apremilast)

Report: FDA-approved Otezla can dramatically reduce cravings for alcoholПодробнее

Superior risankizumab efficacy vs. apremilast in systemic-eligible moderate psoriasis.Подробнее

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for ...Подробнее

FDA Approves Updated Labeling for Oxycontin TabletsПодробнее

Comparing FDA non-approval letters, and the press releases from sponsorsПодробнее

What are the side effects of Otezla ApremilastПодробнее

Apremilast Study for Behçet's diseaseПодробнее

Mark Lebwohl, MD - Apremilast as an Off-Label Therapeutic AgentПодробнее

FDA denies approval of needle-free epinephrine, requests more data from drugmakerПодробнее

2024.04 Ep 2 New Drug Update: ResmetiromПодробнее

FDA D.I.S.C.O. Burst Edition: FDA approval of Padcev (enfortumab vedotin-ejfv) with Keytruda (pem...Подробнее

FDA D.I.S.C.O. Burst Edition: FDA approval of Lytgobi (futibatinib) for adult patients with previ...Подробнее

Expanding Treatment Options for Youth with PsoriasisПодробнее

FDA D.I.S.C.O. Burst Edition: FDA approval of Omisirge (omidubicel-onlv) to reduce time to neutro...Подробнее

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced ...Подробнее

Otezla (Apremilast)Подробнее

FDA D.I.S.C.O. Burst Edition: FDA approval of Zynyz (retifanlimab-dlwr) for metastatic or recurre...Подробнее

FDA D.I.S.C.O. Burst Edition: FDA approval of ABECMA (idecabtagene vicleucel) the first FDA appro...Подробнее